Development pipeline

Select programs in development, Phase 1 through Approval (removed after programs achieve approval in both US/EU)

Learn more

Novel therapies

Select Novel Therapy programs recently approved or with potential filings in the US/EU within a specified window as outlined in the Enterprise Business Review.

Learn more

2024 Key events

Major US/EU approvals and submissions and phase 2/3 clinical data presentations being planned or achieved for the year.

Learn more

U.S. patent expiry tables

Information about our pharmaceutical patent portfolio.

Learn more
Questions? Please contact us: